Should I Buy ACB? ACB 2026 Analysis

Should You Buy Aurora Cannabis Inc (ACB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.660

1 Day change

1.39%

52 Week Range

6.670

Analysis Updated At

2026/04/16

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Aurora Cannabis Inc (ACB) is not a strong buy at this time for a beginner investor with a long-term focus. Despite some positive catalysts, the company's financial performance and lack of strong trading signals do not suggest an immediate entry point.

Technical Analysis

The MACD is positive and contracting, indicating a potential upward trend. RSI is neutral at 65.107, and moving averages are converging, suggesting indecision in price movement. Key support is at 3.313, and resistance is at 3.676. The stock is trading near its pivot level, showing no clear breakout or breakdown.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low open interest put-call ratio indicates bullish sentiment, but the higher option volume put-call ratio suggests short-term bearish sentiment.

Technical Summary

Sell

Buy

Positive Catalysts

Aurora's acquisition of Safari Flower Company enhances its position in the international medical cannabis market and expands its EU GMP-certified production capacity. The company expects positive EBITDA contributions from the acquisition starting in fiscal year 2027.

Neutral/Negative Catalysts

Net income and EPS have dropped significantly YoY, with net income down 93.63% and EPS down 94.23%. This raises concerns about profitability and operational efficiency in the short term.

Financial Performance

In Q3 2026, revenue increased by 6.79% YoY, and gross margin improved by 69.91% YoY. However, net income and EPS saw significant declines, indicating profitability challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a Buy rating with a reduced price target of C$9, down from C$10. Analysts highlight Aurora's leadership in the medical cannabis market and its expansion into high-margin international markets.

3 Analyst Rating

Wall Street analysts forecast ACB stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.610

Low

6.28

Averages

6.77

High

7.39

Current: 3.610

Low

6.28

Averages

6.77

High

7.39

Canaccord

Buy

downgrade

$10 -> $9

AI Analysis

2026-02-05

Reason

Canaccord

Price Target

$10 -> $9

AI Analysis

2026-02-05

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Aurora Cannabis to C$9 from C$10 and keeps a Buy rating on the shares.

Canaccord

Buy

initiated

$10

2026-01-27

Reason

Canaccord

Price Target

$10

2026-01-27

initiated

Buy

Reason

Canaccord initiated coverage of Aurora Cannabis with a Buy rating and C$10 price target. The medical-first operator is "the leading medical player" in Canada and "a foremost player" in the key international markets of Germany, Poland, Australia, and the UK, the analyst tells investors in a note starting coverage of the the Canadian cannabis group. A domestic pivot supported an expansion into the high-margin international markets, where gross margins are roughly 2.5-times higher, on average, than in Aurora's medically focused Canadian business, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACB

Unlock Now

ACB Should I Buy

ACB Should I Buy

Should You Buy Aurora Cannabis Inc (ACB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch